The Doctors Who Actually Know Things Have Spent Twenty Years Being Cited and Never Credited. Aimwell Partners Inc. Is Building the Network That Puts Their Names on the RecordAimwell Partners Inc. (OTCID:AIMN) publishes the contributor page of Christopher A. Jones, PhD, FRSM, as its Federated Health Intelligence Network expands through credentialed professional referral. Additional named contributors and technology collaborations are expected to be announced in the coming weeks.
Aimwell Partners Inc. (OTC:AIMN) Confirms Advanced Discussions With Curated Life Sciences Capital NetworkMIAMI, FL / ACCESS Newswire / July 15, 2026 / Aimwell Partners Inc. (OTCID:AIMN), parent company of AimwellBio, today confirmed it is engaged in advanced discussions with an exclusive, referral-based life sciences capital markets network that connects biotechnology companies with institutional investors, banking relationships, strategic advisors, and other participants across the biotech investment ecosystem.
Aimwell Partners Inc. (OTC: AIMN) Enters Final Negotiations to Acquire Healthcare Intellectual Property Independently Valued at $10 MillionMIAMI, FL / ACCESS Newswire / July 13, 2026 / Aimwell Partners Inc. (OTCID:AIMN) today announced that it has entered final-stage negotiations to acquire a portfolio of healthcare-related intellectual property that has been independently valued at approximately $10 million.
The Professionals Arrived First - Now Their Institutions are Following: Aimwell Partners Inc. Confirms Enterprise Interest Driven by Its Credentialed Observer NetworkMIAMI, FL / ACCESS Newswire / July 8, 2026 / Aimwell Partners Inc. (OTCID:AIMN) - Technology adoption rarely begins with procurement. It begins with the professionals doing the work.
Every AI Intelligence Platform Asks the Market to Trust Its Numbers. Aimwell Partners Inc. (OTC:AIMN) Just Opened the Data419 regulatory, clinical, and research signals are now publicly available at aimwellbio.com/signals-no login, no sales call, and no requirement to take the company's word for anything.
Aimwell Partners Inc. Publishes the Adversarial Validation Standard, v1, an Open Methodology Framework for Verifying AI-Generated Biopharma IntelligenceMIAMI, FL / ACCESS Newswire / July 1, 2026 / Aimwell Partners Inc. (OTCID:AIMN) ("Aimwell" or the "Company"), the parent company of AimwellBio, today announced the publication of the Adversarial Validation Standard, v1, a versioned, open methodology framework designed to establish a transparent reference for decision integrity in AI-generated biopharmaceutical intelligence.
AimwellBio Continues Onboarding Healthcare Professionals to Its Verified Observer Network, Adds One-Click LinkedIn SignupAimwell Partners Inc. (OTC PINK:AIMN) is actively onboarding doctors, scientists, researchers, and capital professionals into AimwellBio Observer, a credentialed intelligence network where members read source-traced signals across biopharma. A new LinkedIn connect flow makes applying faster. Complimentary access is currently available for approved professionals. Credentialing required.
AIMN: As Healthcare Breaches Hit a Record and Move to Third-Party Providers, AimwellBio.com Explores a Redundancy Layer Built to Survive the VendorWith over one billion Americans' health records now breached and the largest incidents shifting to mission-critical third parties, Aimwell Partners Inc. is exploring verified infrastructure that adds redundancy rather than another patch
AimwellBio Expands Platform Capabilities to Strengthen the Infrastructure Behind Trusted Healthcare IntelligenceDENVER, CO / ACCESS Newswire / June 17, 2026 / Aimwell Partners Inc. (OTCID:AIMN) today announced an expansion of technical capabilities supporting AimwellBio, the Company's healthcare intelligence platform focused on verified professional participation and trusted decision intelligence.
